The global small molecule drug discovery market is experiencing significant growth due to increasing demand for innovative therapeutics targeting chronic diseases, cancer, neurological disorders, and infectious diseases. The market was valued at USD 61.28 billion in 2025 and is projected to grow from USD 66.34 billion in 2026 to USD 126.91 billion by 2034, registering a CAGR of 8.45% during the forecast period.
Small molecule therapeutics continue to dominate modern drug development because of their oral bioavailability, cost-effectiveness, scalability, and ability to target intracellular pathways. Advancements in artificial intelligence (AI), high-throughput screening (HTS), structure-based drug design, and cheminformatics are accelerating drug discovery timelines while improving precision and efficiency.
AI-Based Drug Design Revolutionizing Small Molecule Discovery
Artificial intelligence is transforming the pharmaceutical industry by enabling faster target identification, lead optimization, and predictive modeling for small molecule therapeutics. Pharmaceutical companies are increasingly collaborating with AI-driven biotech firms to accelerate research and improve drug development success rates.
For instance, Takeda Pharmaceutical Co Ltd partnered with Iambic Therapeutics in February 2026 to leverage AI technology for the development of novel small molecule drugs targeting cancer and gastrointestinal diseases.
Similarly, Insilico Medicine collaborated with Qilu Pharmaceutical Group to utilize its Pharma.AI platform for the development of small molecule inhibitors. These collaborations are accelerating innovation and reducing overall drug discovery costs across the pharmaceutical ecosystem.
Rising Burden of Chronic Diseases Driving Market Demand
The increasing prevalence of chronic and complex diseases such as cancer, cardiovascular disorders, autoimmune diseases, and neurological conditions is a major factor fueling market expansion. Small molecule drugs remain highly preferred due to their effectiveness, ease of administration, and suitability for long-term treatment.
Pharmaceutical companies are significantly increasing investments in research pipelines focused on kinase inhibitors, oral antivirals, targeted therapies, and precision medicine solutions. According to the U.S. FDA Center for Drug Evaluation and Research (CDER), 28 out of 36 newly approved drugs in 2025 were small molecule therapeutics, highlighting their continued regulatory dominance.
High-Throughput Screening Technologies Accelerate Innovation
Technological advancements in high-throughput screening (HTS) systems are transforming early-stage drug discovery processes. Automated liquid handling systems, multiplexed screening platforms, and acoustic droplet technologies are enabling researchers to evaluate thousands of compounds rapidly and efficiently.
Companies such as Thermo Fisher Scientific Inc. and Beckman Coulter are enhancing assay sensitivity and throughput capabilities through advanced HTS instrumentation. These innovations significantly reduce discovery timelines and improve the identification of high-potential drug candidates.
Targeted Protein Degradation Emerging as a Key Trend
The market is increasingly shifting toward targeted protein degradation technologies such as PROTACs (Proteolysis Targeting Chimeras), which allow selective degradation of disease-causing proteins rather than simple inhibition.
Companies including Arvinas, Inc. are actively developing next-generation small molecule therapeutics utilizing targeted protein degradation approaches. These technologies are expanding treatment possibilities for previously undruggable diseases and improving therapeutic outcomes across oncology and rare disease applications.
North America Leads Global Market While Asia Pacific Emerges as Fastest-Growing Region
North America dominated the small molecule drug discovery market with a revenue share of 39.52% in 2025. Strong government funding, advanced biotechnology infrastructure, and increasing AI integration in pharmaceutical R&D continue to support regional leadership.
The United States remains the largest contributor to regional growth due to extensive investments in drug discovery automation, medicinal chemistry, and RNA-targeting therapies. Companies such as Excelsior Sciences secured substantial funding to enhance AI-ready chemistry workflows and automated compound synthesis capabilities.
Meanwhile, Asia Pacific is projected to register the fastest CAGR of 10.44% during the forecast period. Countries including China, India, and Japan are rapidly strengthening their pharmaceutical research ecosystems through government-backed initiatives, contract research outsourcing, and advanced biotech infrastructure.
China’s expanding biotech clusters and regulatory modernization efforts are accelerating small molecule innovation, while India continues to emerge as a cost-effective destination for outsourced drug discovery services.
Synthetic Small Molecules Segment Maintains Dominance
Based on drug type, the Synthetic Small Molecules segment held the largest market share of 42.31% in 2025. Their oral bioavailability, chemical stability, and scalable manufacturing processes make synthetic compounds highly preferred for oncology, cardiovascular, and pain management therapies.
By technology, the High-Throughput Screening segment dominated the market with a share of 29.72% in 2025, while DNA-Encoded Library Screening is anticipated to witness the fastest growth during the forecast period due to its ability to identify potent compounds rapidly and cost-effectively.
Pharmaceutical Companies Continue Leading Market Adoption
Pharmaceutical companies accounted for the largest end-user share of 44.30% in 2025 due to extensive investments in drug discovery research, clinical trials, and commercialization capabilities. Biotechnology companies are also witnessing rapid expansion by leveraging AI-driven platforms, targeted therapeutics, and precision medicine technologies to accelerate small molecule development.
Competitive Landscape Intensifies with AI and CRO Expansion
The competitive landscape remains moderately fragmented with major pharmaceutical companies, contract research organizations (CROs), and AI-driven biotech firms competing aggressively to expand their discovery capabilities.
Key market participants include:
- Evotec SE
- WuXi AppTec
- ChemPartner
- Atomwise Inc.
- Pfizer Inc.
- Novartis AG
- AstraZeneca
- Schrödinger, Inc.
- Charles River Laboratories
- GSK plc
Recent collaborations between pharmaceutical giants and AI-focused biotech companies are reshaping the market by accelerating candidate selection, improving hit discovery success rates, and reducing overall development timelines.
About Us:
Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.
Contact Us:
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
